TrimRx vs Hims: Compounded Specialist vs Branded GLP-1 Public Company
TrimRx and Hims are technically both in our brand-name GLP-1 category, but they're shaped very differently. TrimRx is a cash-pay compounded specialist that also handles brand-name fulfillment as a secondary path; Hims is a publicly-traded multi-vertical platform that became an authorized Novo Nordisk seller of branded Wegovy and Ozempic in March 2026. The right pick depends almost entirely on whether you have insurance covering branded medication.
TrimRx
4.3LegitScript-certified compounded GLP-1 telehealth
Hims & Hers
3.4Public-company telehealth, post-settlement branded-only GLP-1 supply
Reviewed by Designing Longevity Editorial·Last verified May 1, 2026
Bottom line
If you have commercial insurance covering Wegovy or Ozempic, Hims is the clearer pick: authorized Novo seller post-March 2026 settlement, oral Wegovy pill access, and a savings-card pathway that can land effective monthly cost at $0-$25. If you're cash-pay and looking at compounded GLP-1, TrimRx is materially better: stronger accreditation stack (LegitScript-certified plus BBB-accredited B), no FDA enforcement action, and all-inclusive pricing that beats Hims's branded-only post-settlement model. The asymmetry is the point: these two aren't really competing for the same user.
Side-by-side at a glance
Who wins for each use case
We pick a winner per criterion and explain the reasoning. Skip to whichever rows match how you'd actually use the platform.
Insurance pathway for branded Wegovy or Ozempic
Winner: Hims & HersHims is now an authorized Novo Nordisk seller of branded Wegovy and Ozempic per the March 2026 settlement, with prior-authorization support and manufacturer-savings-card eligibility that can drop effective monthly cost to $0-$25 for users with eligible commercial insurance. TrimRx mentions handling brand-name prior authorization as a secondary path but is built around the cash-pay compounded model; the program is not optimized for the insurance pathway.
Cash-pay compounded GLP-1 (still available)
Winner: TrimRxPer the March 2026 Novo settlement, Hims agreed to stop advertising compounded GLP-1 entirely; new patients there get branded only. TrimRx still serves cash-pay compounded semaglutide and tirzepatide as its primary product. If compounded is what you actually want, TrimRx is one of two viable choices in this matchup, and Hims is no longer the other one.
Accreditation stack
Winner: TrimRxTrimRx has the strongest accreditation stack in the compounded cohort: LegitScript Healthcare Merchant certification, BBB-Accredited with a B rating, and partner pharmacies that are LegitScript-certified. Hims is BBB Accredited A+ since 2018, which is strong, but doesn't carry an equivalent LegitScript certification on the GLP-1 side. For users weighting compounding-specific accreditation, TrimRx wins; for users weighting general BBB tenure, Hims wins.
Regulatory and legal track record
Winner: TrimRxHims received twin FDA warning letters on September 9, 2025 for false or misleading marketing of compounded semaglutide and went through a public dispute with Novo Nordisk before the March 2026 settlement. TrimRx has no FDA warning letters, no Form 483 inspection observations, and no active manufacturer lawsuits at capture date. On the cleanest-record criterion, TrimRx wins outright.
Customer service and review platform signals
Winner: TrimRxHims runs at Trustpilot 3.0/5 across roughly 8,000 reviews with 28% one-star ratings (a bimodal distribution that signals a large slice of unhappy users). TrimRx Trustpilot pattern is materially better, around 4.5+ on a smaller sample. BBB favors Hims (A+ vs B), but the wider review set leans TrimRx.
New oral Wegovy pill access
Winner: Hims & HersHims is one of the first telehealth channels to offer the FDA-approved oral Wegovy pill in early 2026, explicitly priced at $149/month medication plus membership. TrimRx does not carry the branded oral Wegovy pill. If oral Wegovy specifically is what you want, Hims is the answer.
Public-company financial disclosure
Winner: Hims & HersHims is publicly traded as NYSE: HIMS, with quarterly 10-Qs and audited financials in the public record. TrimRx is private (operated by MetaFit Pharma Solutions LLC, San Diego). For users who weight financial-transparency as a trust signal, Hims wins this row by definition.
All-inclusive cash-pay pricing
Winner: TrimRxTrimRx bundles consult, prescription, medication, and shipping into one monthly price ($179-$259/month for compounded semaglutide and tirzepatide). Hims runs a membership-plus-medication model where the membership ($39 first month, $149/month standard) is on top of medication cost, and the post-settlement product is branded-only at retail or insurance-mediated pricing. For cash-pay users without insurance, TrimRx's all-inclusive math is materially better.
Rubric scores side-by-side
Same six dimensions we use on every provider profile, weighted to a single 0-5 score. Click through to either profile for the verification details behind each row.
Licensure 20% weight
Accreditation 20% weight
Transparency 20% weight
Product quality 15% weight
Pricing 15% weight
Customer service 10% weight
Pricing in plain terms
TrimRx: all-inclusive compounded GLP-1 at $179-$259/month bundling consult, Rx, and medication. No insurance pathway; not built for branded medication. Hims: $39 first month, $149/month standard membership plus medication. Branded oral Wegovy at $149/month medication; injectable Wegovy/Ozempic via insurance + Novo savings card can land at $0-$25/month effective for eligible users; cash-pay branded is materially higher. The simplest decision rule: insurance covers branded → Hims; cash-pay compounded → TrimRx. There's not much overlap in the middle.
Read the full profiles
This comparison summarizes the head-to-head call. The full provider profiles include verification items, regulatory history, public-review aggregation, and the signup walkthrough.